Post-acute COVID-19 associated with evidence of bystander T-cell activation and a recurring antibiotic-resistant bacterial pneumonia.


Journal

eLife
ISSN: 2050-084X
Titre abrégé: Elife
Pays: England
ID NLM: 101579614

Informations de publication

Date de publication:
17 12 2020
Historique:
received: 24 09 2020
accepted: 16 12 2020
pubmed: 18 12 2020
medline: 12 1 2021
entrez: 17 12 2020
Statut: epublish

Résumé

Here, we describe the case of a COVID-19 patient who developed recurring ventilator-associated pneumonia caused by

Identifiants

pubmed: 33331820
doi: 10.7554/eLife.63430
pii: 63430
pmc: PMC7775105
doi:
pii:

Substances chimiques

Anti-Bacterial Agents 0
Piperacillin, Tazobactam Drug Combination 157044-21-8
Meropenem FV9J3JU8B1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : UKRI
ID : MR/S019553/1
Pays : International
Organisme : Cystic Fibrosis Trust
ID : CF Trust SRC 015
Pays : International
Organisme : UK Research and Innovation
ID : MR/R02622X/1
Pays : International
Organisme : Department of Health
ID : DRF-2018-11-ST2-065
Pays : United Kingdom
Organisme : UKRI
ID : MR/R02622X/1
Pays : International
Organisme : Medical Research Council
ID : MR/R02149X/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 212258/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J014370/1
Pays : United Kingdom
Organisme : UK Research and Innovation
ID : MR/S019553/1
Pays : International
Organisme : Medical Research Council
ID : MR/V027506/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M501621/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/H005439/1
Pays : United Kingdom

Informations de copyright

© 2020, Gregorova et al.

Déclaration de conflit d'intérêts

MG, DM, TB, JS, FH, MA, DA, MT, AH, HB, CR, MA, AD, MS, EO, AG, AF, LW, BA, RB, DA, DB, CM, JS, SN, CC, NL, MC, LR, RM No competing interests declared

Références

Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Genome Res. 2017 May;27(5):737-746
pubmed: 28100585
Curr Opin Immunol. 2012 Aug;24(4):476-81
pubmed: 22554789
Nat Biotechnol. 2019 May;37(5):540-546
pubmed: 30936562
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
J Bacteriol. 2003 Oct;185(20):6195-8
pubmed: 14526032
BMC Genomics. 2011 Aug 08;12:402
pubmed: 21824423
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Antimicrob Agents Chemother. 2006 May;50(5):1633-41
pubmed: 16641429
J Exp Med. 2000 Apr 17;191(8):1269-80
pubmed: 10770795
Exp Mol Med. 2019 Dec 11;51(12):1-9
pubmed: 31827070
Nat Immunol. 2020 Nov;21(11):1336-1345
pubmed: 32887977
Appl Environ Microbiol. 2000 Dec;66(12):5488-91
pubmed: 11097934
BMJ. 2020 Aug 11;370:m3026
pubmed: 32784198
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Bioinformatics. 2012 Oct 1;28(19):2520-2
pubmed: 22908215
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
Nat Rev Microbiol. 2015 Jan;13(1):42-51
pubmed: 25435309
ISME J. 2009 Feb;3(2):168-78
pubmed: 19005498
Genome Res. 2004 Jul;14(7):1394-403
pubmed: 15231754
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Clin Microbiol Infect. 2018 Mar;24(3):258-266
pubmed: 28648860
Clin Microbiol Infect. 2003 Jun;9(6):467-74
pubmed: 12848721
Thorax. 2020 Dec 3;:
pubmed: 33273026
PLoS Pathog. 2010 Aug 19;6(8):e1001051
pubmed: 20808900
Wellcome Open Res. 2018 Sep 24;3:124
pubmed: 30345391
Sci Transl Med. 2015 Mar 11;7(278):278ra35
pubmed: 25761891
Am J Respir Crit Care Med. 2015 Jun 1;191(11):1250-64
pubmed: 25789411
Genome Biol. 2019 Nov 28;20(1):257
pubmed: 31779668

Auteurs

Michaela Gregorova (M)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Daniel Morse (D)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Tarcisio Brignoli (T)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Joseph Steventon (J)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Fergus Hamilton (F)

North Bristol NHS Trust, Bristol, United Kingdom.

Mahableshwar Albur (M)

North Bristol NHS Trust, Bristol, United Kingdom.

David Arnold (D)

North Bristol NHS Trust, Bristol, United Kingdom.

Matthew Thomas (M)

North Bristol NHS Trust, Bristol, United Kingdom.

Alice Halliday (A)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Holly Baum (H)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Christopher Rice (C)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Matthew B Avison (MB)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Andrew D Davidson (AD)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Marianna Santopaolo (M)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Elizabeth Oliver (E)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Anu Goenka (A)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Adam Finn (A)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Linda Wooldridge (L)

Bristol Veterinary School in the Faculty of Health Sciences, Bristol, United Kingdom.

Borko Amulic (B)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Rosemary J Boyton (RJ)

Department of Infectious Disease, Imperial College London, London, United Kingdom.
Lung Division, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Daniel M Altmann (DM)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

David K Butler (DK)

Department of Infectious Disease, Imperial College London, London, United Kingdom.

Claire McMurray (C)

Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.

Joanna Stockton (J)

Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.

Sam Nicholls (S)

Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.

Charles Cooper (C)

Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.

Nicholas Loman (N)

Institute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.

Michael J Cox (MJ)

Lung Division, Royal Brompton & Harefield NHS Foundation Trust, London, United Kingdom.

Laura Rivino (L)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Ruth C Massey (RC)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH